Shanghai Fosun Pharmaceutical (Group) Co.'s (HKG:2196) independently developed small molecule oral DPP-1 inhibitor, XH-S004, has been approved for clinical trials in China for the treatment of chronic obstructive pulmonary disease (COPD).
XH-S004 is also being trialed for the treatment of non-cystic fibrosis bronchiectasis, according to its Hong Kong bourse filing on Friday.
As of April, the Group had invested about 61 million yuan in the research and development of XH-S004.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。